/ /

Ron Rajecki
Aflibercept fares well in treating DME
Intravitreal aflibercept 2 mg every 8 weeks after 5 initial monthly doses (IVT-AFL 2q8) improved visual acuity outcomes in eyes with center-involved diabetic macular edema (DME) to a greater extent than intravitreal ranibizumab 0.5 mg as needed (IVR 0.5 mg PRN), though vascular endothelial growth factor (VEGF) inhibition with either IVT-AFL or IVR is efficacious and appears safe
Trifocal lens receives European CE mark
Alcon has received European CE mark for a trifocal IOL (AcrySof IQ PanOptix) designed for patients who are undergoing cataract surgery and want to address their near, intermediate, and distance vision needs with one lens.
OCT could assist in laser tissue bonding of corneal incisions
A laser tissue bonding apparatus integrated with an optical coherence tomography (OCT) probe is a plausible instrument that allows for temperature-controlled laser bonding of incisions in the cornea, according to Israeli researchers. The OCT probe can provide real-time feedback of structural change of the corneal tissue, and indicate the progress and end point of the bonding.
Who will benefit most from cataract surgery?
A team of researchers from Denmark believes it has found a way for ophthalmologists to identify the patients who will most likely to benefit from age-related cataract surgery.
Gaming headset could offer a win for glaucoma patients
A gaming headset is helping researchers address balance issues in patients who have glaucoma.
PKal May Join VEGF as DME pathway
A protein called PKal (plasma kallikrein) and its associated molecules are key players in an inflammatory molecular pathway involved in diabetic macular edema, according to a study published in Diabetes.
Glaucoma drug granted orphan status
The European Medicines Agency (EMA) has granted orphan drug designation to ISTH0036, a locked nucleic acid-modified antisense oligonucleotide under development by Munich-based Isarna Therapeutics, for the prevention of scarring after glaucoma filtration surgery (GFS).
Second blood-vessel-growth protein implicated in PDR
Targeting the blood-vessel-growth protein angiopoietin-like 4 (ANGPTL4) along with anti-vascular endothelial growth factor (VEGF) therapy could increase the effectiveness of treatments for the prevention of proliferative diabetic retinopathy (PDR), according to researchers at The Johns Hopkins University and the University of Maryland.
Bionic lens can restore high-quality vision
An optometrist in British Columbia has developed an IOL that his company’s website says “is capable of restoring quality vision at all distances, without glasses, contact lenses or corneal refractive procedures, and without the vision problems that have plagued current accommodative and multifocal [IOL] designs.”
Glaucoma may be linked to allergens
The immune system may play a role in the development of glaucomatous optic neuropathy, according to the results of a newly published study.


View Results